Lifitegrast

• CAT Number: I007669
• CAS Number: 1025967-78-5
• Molecular Formula: C₂₉H₂₄Cl₂N₂O₇S
• Molecular Weight: 615.48
• Purity: 97%
• Synonyms: SAR-1118; SAR 1118; SAR1118; Lifitegrast, brand name: Xiidra.;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid
• Target: Integrin
• Target Protein: P05362
• Solubility: Soluble in DMSO, not in water
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: IC50:2.98 nM
• IUPAC Name: (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
• InChI: InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
• InChIKey: JFOZKMSJYSPYLN-QHCPKHFHSA-N
• SMILES: CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl

Lifitegrast (Cat No.: I007669), also known as SAR-1118, is an LFA-1 antagonist primarily developed for the treatment of vascular complications of the eye. By inhibiting T cell-mediated inflammation, lifitegrast exerts its therapeutic effects by blocking the interaction between two key cell surface proteins, lymphocyte function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM-1). This interaction plays a crucial role in the recruitment and activation of inflammatory cells. By disrupting this interaction, lifitegrast reduces overall inflammatory responses and holds potential for managing ocular conditions associated with vascular complications.

Reference

1:Lifitegrast (Xiidra) for Dry Eye Disease. [No authors listed]JAMA. 2017 Apr 11;317(14):1473-1474. doi: 10.1001/jama.2016.12872. No abstract available. PMID: 28399249
2:Lifitegrast, Bezlotoxumab, and Sugammadex sodium. Hussar DA, Cheeseman RS 2nd.J Am Pharm Assoc (2003). 2017 Mar – Apr;57(2):284-287. doi: 10.1016/j.japh.2017.02.004. No abstract available. PMID: 28285777
3:Lifitegrast: A novel drug for treatment of dry eye disease. Abidi A, Shukla P, Ahmad A.J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):194-198. doi: 10.4103/0976-500X.195920. PMID: 28163544 Free PMC Article
4:Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A.Ophthalmology. 2017 Jan;124(1):53-60. doi: 10.1016/j.ophtha.2016.09.025. Epub 2016 Oct 27. PMID: 28079022 Free Article
5:Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease. Keating GM.Drugs. 2017 Feb;77(2):201-208. doi: 10.1007/s40265-016-0681-1. Review. PMID: 28058622
6:Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease. Paton DM.Drugs Today (Barc). 2016 Sep;52(9):485-493. PMID: 27883115
7:Lifitegrast (Xiidra) for dry eye disease. [No authors listed]Med Lett Drugs Ther. 2016 Aug 29;58(1502):110-1. No abstract available. Corrected and republished in: JAMA. 2017 Apr 11;317(14 ):1473-1474. PMID: 27552207
8:Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials. Holland EJ, Whitley WO, Sall K, Lane SS, Raychaudhuri A, Zhang SY, Shojaei A.Curr Med Res Opin. 2016 Jul 22:1-7. [Epub ahead of print] PMID: 27388660
9:Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Semba CP, Gadek TR.Clin Ophthalmol. 2016 Jun 10;10:1083-94. doi: 10.2147/OPTH.S110557. eCollection 2016. Review. PMID: 27354762 Free PMC Article
10:Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. Donnenfeld ED, Karpecki PM, Majmudar PA, Nichols KK, Raychaudhuri A, Roy M, Semba CP.Cornea. 2016 Jun;35(6):741-8. doi: 10.1097/ICO.0000000000000803. PMID: 27055211 Free PMC Article